Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Cipla
Medtronic
Queensland Health
Express Scripts
Mallinckrodt
Merck
Dow
Argus Health

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,919,461

« Back to Dashboard

Summary for Patent: 7,919,461
Title:Erythropoietin receptor peptide formulations and uses
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Inventor(s): Duliege; Anne-Marie (Palo Alto, CA), Stead; Richard (Bellevue, WA), Leuther; Kerstin (San Jose, CA), Woodburn; Kathryn Wynne (Campbell, CA), Naso; Robert Barnett (Menlo Park, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Application Number:11/777,500
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,919,461

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-001 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,919,461

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,550,433 Erythropoietin receptor peptide formulations and uses ➤ Try a Free Trial
7,906,485 Erythropoietin receptor peptide formulations and uses ➤ Try a Free Trial
8,324,159 Erythropoietin receptor peptide formulations and uses ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,919,461

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 92497 ➤ Try a Free Trial
Singapore 162747 ➤ Try a Free Trial
New Zealand 563433 ➤ Try a Free Trial
Norway 20076634 ➤ Try a Free Trial
Mexico 2007015303 ➤ Try a Free Trial
Morocco 29557 ➤ Try a Free Trial
South Korea 20120119921 ➤ Try a Free Trial
South Korea 20080021115 ➤ Try a Free Trial
Japan 2013173763 ➤ Try a Free Trial
Japan 2010536858 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Teva
Baxter
Chinese Patent Office
Julphar
US Army
Dow
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot